ArticleCase reports in gastrointestinal medicine2025
Kava Herb-Induced Liver Injury as Verified by the Updated RUCAM.
Article in Case reports in gastrointestinal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating the Pattern of Kava (Piper methysticum) Consumption in Australia by Wastewater-Based Epidemiology.Drug and alcohol review · 2026Article
- Kava Herb-Induced Liver Injury as Verified by the Updated RUCAM.Case reports in gastrointestinal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A temporal relationship between liver enzyme derangement and an herbal remedy warrants further assessment for herb-induced liver injury (HILI). Here, we describe the use of kava, a drink traditionally consumed in Pacific Island cultures, causing acute ALT and AST elevation as assessed by an updated RUCAM score of 7. The increasing use of kava in Western society should prompt clinicians to be more aware of this rare cause of HILI. A 46-year-old man was referred to the emergency department with a 3-week history of fatigue, right upper quadrant pain, and profound transaminitis. He commenced kava 10 g daily 5 weeks prior to aid sleep, which was ceased 2 weeks prior due to his biochemical derangement. Blood tests revealed an ALT of 1546 U/L and an AST of 920 U/L. An autoimmune screen, viral serology, and liver ultrasound showed no abnormalities. A liver biopsy revealed foci of hepatocellular necrosis with scattered ballooning degeneration and apoptotic bodies in the parenchyma, but normal underlying hepatic parenchyma without steatosis. Following cessation of kava, the liver enzymes improved without any other intervention. He was monitored as an outpatient and had no recurrence. The incidence of kava HILI may increase with its marketing; its exact mechanism is unknown. Ultimately, further research is needed to identify the pathogenesis of kava HILI. HILI is a significant cause of transaminitis, and clinicians should remain vigilant in patients presenting with nonspecific symptoms and a negative liver screen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.